专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11897916B2 Mogrosides, compositions and their purification 有权
公开(公告)号：US11897916B2
公开(公告)日：2024-02-13
申请号：US16867070
申请日：2020-05-05
申请人： The Coca-Cola Company
发明人： Indra Prakash , Venkata Sai Prakash Chaturvedula
IPC分类号： C07J17/00 , A23L27/30 , A23L2/38 , A23L2/60
CPC分类号： C07J17/005 , A23L2/38 , A23L2/60 , A23L27/36 , A23V2002/00
摘要： Novel mogrosides and methods for heir purification are provided herein. In addition, compositions comprising said novel mogrosides and methods for preparing the same are provided.

2. 发明授权

US11858958B2 Blank liposome with ginsenoside Rg3 or its analog as membrane materials and preparations and uses thereof 有权
公开(公告)号：US11858958B2
公开(公告)日：2024-01-02
申请号：US16961899
申请日：2019-11-29
申请人： Shanghai Ginsome Pharmatech Co., Ltd.
发明人： Jianxin Wang , Chao Hong , Ying Zhu , Jiaxuan Xia , Dan Wang , Yingjiang Chen , Huaxing Zhan
IPC分类号： C07J17/00 , A61P35/00 , A61K9/127 , A61K47/28 , A61K45/06 , C07B63/04
CPC分类号： C07J17/005 , A61K9/1277 , A61K47/28 , A61P35/00 , A61K45/06 , C07B63/04
摘要： The present invention provides a blank liposome with ginsenoside Rg3 or its analog as the membrane material, preparations and uses thereof. The disclosed blank liposome has a membrane comprising a lipid and a ginsenoside analog of Formula I, presenting remarkable advantages in film formation, encapsulation efficiency, targeted drug delivery, blood circulation time, stability, safety and homogeneity. It can also be used to load active substances of drugs and cosmetics, biological agents, polynucleotides or oligonucleotides, and the preparation process is convenient.

3. 发明授权

US11851457B2 Oxysterols and methods of use thereof 有权
公开(公告)号：US11851457B2
公开(公告)日：2023-12-26
申请号：US17395155
申请日：2021-08-05
申请人： Sage Therapeutics, Inc.
发明人： Francesco G. Salituro , Albert Jean Robichaud , Gabriel Martinez Botella , Boyd L. Harrison , Andrew Griffin
IPC分类号： C07J9/00 , C07J17/00 , A61P25/20 , A61P25/28 , A61P25/22 , A61P19/02 , A61P25/18 , A61P1/00 , A61P25/16 , A61P35/00 , C07J43/00
CPC分类号： C07J9/00 , A61P1/00 , A61P19/02 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/28 , A61P35/00 , C07J17/00 , C07J43/003
摘要： Compounds are provided according to Formula (I):

and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

4. 发明公开

US20230391816A1 NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF 审中-公开
公开(公告)号：US20230391816A1
公开(公告)日：2023-12-07
申请号：US18455007
申请日：2023-08-24
申请人： Sage Therapeutics, Inc.
发明人： Boyd L. Harrison , Gabriel Martinez Botella , Albert Jean Robichaud , Francesco G. Salituro
IPC分类号： C07J41/00 , C07J5/00 , C07J7/00 , C07J17/00
CPC分类号： C07J41/005 , C07J5/0015 , C07J1/0011 , C07J17/00 , C07J7/009 , C07J7/002
摘要： Described herein are steroids of Formula (I):

and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

5. 发明公开

US20230382945A1 THERAPEUTIC AGENTS AND METHODS 审中-公开
公开(公告)号：US20230382945A1
公开(公告)日：2023-11-30
申请号：US18143457
申请日：2023-05-04
申请人： Pop Test Oncology LLC
发明人： Randice Lisa ALTSCHUL , Neil David THEISE , Andreas J. KESEL , Myron RAPKIN , Rebecca O'Brien , Anthony R. ARMENT
IPC分类号： C07J17/00 , A61K31/175 , C07D307/83 , C07H19/06 , C07C309/50 , C07C211/63 , C07C335/40 , A61K31/58 , A61K31/695 , A61K31/343 , A61K31/7068 , A61K31/655 , A61K31/567 , A61K31/137 , A61K31/14 , C07F7/08
CPC分类号： C07J17/00 , A61K31/175 , C07D307/83 , C07H19/06 , C07C309/50 , C07C211/63 , C07C335/40 , A61K31/58 , A61K31/695 , A61K31/343 , A61K31/7068 , A61K31/655 , A61K31/567 , A61K31/137 , A61K31/14 , C07F7/0812
摘要： The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

6. 发明公开

US20230365617A1 SAPONIN DERIVATIVES FOR USE IN MEDICINE 审中-公开
公开(公告)号：US20230365617A1
公开(公告)日：2023-11-16
申请号：US18012698
申请日：2021-06-23
申请人： SAPREME TECHNOLOGIES B.V.
发明人： Ruben POSTEL , Guy HERMANS , Hendrik FUCHS
IPC分类号： A61K47/54 , A61K47/68 , A61P35/00 , C07J17/00 , A61K36/48
CPC分类号： C07J17/005 , A61K36/48 , A61K47/549 , A61K47/6807 , A61K47/6819 , A61P35/00
摘要： The invention relates to a Quillaja saponaria saponin derivative based on a saponin comprising a triterpene aglycone and a first saccharide chain and/or a second saccharide chain, and comprising: an aglycone core structure comprising an aldehyde group which has been derivatised; and/or the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, which has been derivatised; and/or the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy group which has been derivatised. The invention also relates to a first pharmaceutical composition comprising the saponin derivative of the invention. In addition, the invention relates to a pharmaceutical combination comprising the first pharmaceutical composition of the invention and a second pharmaceutical composition comprising any one or more of an antibody-toxin conjugate, a receptor-ligand - toxin conjugate, an antibody-drug conjugate, a receptor-ligand - drug conjugate, an antibody-oligonucleotide conjugate or a receptor-ligand - oligonucleotide conjugate. The invention also relates to the first pharmaceutical composition or the pharmaceutical combination of the invention, for use as a medicament, or use in the treatment or prophylaxis of a cancer, an infectious disease, viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, transthyretin-mediated amyloidosis, or an autoimmune disease. Furthermore, the invention relates to an in vitro or ex vivo method for transferring a molecule from outside a cell to inside said cell, comprising contacting said cell with the molecule and with a saponin derivative of the invention.

7. 发明公开

US20230331768A1 OXYSTEROLS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：US20230331768A1
公开(公告)日：2023-10-19
申请号：US18106073
申请日：2023-02-06
申请人： Sage Therapeutics, Inc.
发明人： Francesco G. Salituro , Albert Jean Robichaud , Gabriel Martinez Botella , Boyd L. Harrison , Andrew Griffin
IPC分类号： C07J43/00 , C07J9/00 , C07J17/00
CPC分类号： C07J43/003 , C07J9/00 , C07J9/005 , C07J17/00
摘要： Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3′ R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

8. 发明申请

US20230118577A1 NEUROACTIVE STEROIDS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME 有权
公开(公告)号：US20230118577A1
公开(公告)日：2023-04-20
申请号：US17792319
申请日：2021-01-12
申请人： Brii Biosciences, Inc.
发明人： Lianhong XU , Guiling ZHAO
IPC分类号： C07J17/00 , C07J43/00
摘要： The invention of this disclosure is directed to a neuroactive steroid (NAS) of a novel structure. This invention is also directed to a pharmaceutical composition comprising the neuroactive steroid (NAS) and salts thereof. The pharmaceutical composition can be used for preventing and/or treating CNS conditions or diseases related to GABA-modulation, such as depression, bipolar disorder, dementia, Huntington's disease, Parkinson's disease, etc. This invention is further directed to a method for treating a CNS disorder in a subject in need thereof.

9. 发明申请

US20220339164A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS 有权
公开(公告)号：US20220339164A1
公开(公告)日：2022-10-27
申请号：US17696605
申请日：2022-03-16
申请人： Suzhou NeuPharma Co., Ltd.
发明人： Xiangping QIAN
IPC分类号： A61K31/585 , C07J17/00 , C07J41/00 , C07J51/00 , C07J43/00 , A61K9/00 , A61K45/06
摘要： Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.

10. 发明申请

US20220259256A1 NEW CRYSTALLINE FORM OF VASCULAR LEAKAGE BLOCKER COMPOUND 有权
公开(公告)号：US20220259256A1
公开(公告)日：2022-08-18
申请号：US17421165
申请日：2020-10-05
申请人： Curacle Co., Ltd.
发明人： Koo Hyeon Ahn , Myung-Hwa Kim , Jung-In Pyo , Chul Su Baek , Sung Hwan Kim
IPC分类号： C07J17/00
摘要： The present invention relates to a crystalline form Of (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy -6-(acetoxytnethyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13 -dimethyl-2,3,4,7,8,9,10.11,12,13,14,15,16,17-tetradecahydro -1H-cyclopenta [a]phenanthrene-17-yl)hept-5-enoate and a blood vessel leak blocker comprising the same. The novel crystalline form has high purity, excellent stability, excellent long-term storage and pharmaceutical stability, and can be used as a vascular leakage blocker, so it is very advantageous in producing high-quality drug substances.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式